Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

Annals of Oncology

Volumn 26, Issue 8, 2015, Pages 1604-1620

  Caplin, Martyn E ^a   Baudin, E ^b   Ferolla, P ^c   Filosso, P ^d   Garcia Yuste, M ^e   Lim, E ^f   Oberg, K ^g   Pelosi, G ^h   Perren, A ⁱ   Rossi, R E ^a,j   Travis, W D ^k   Bartsch, Detlief ^l   Capdevila, Jaume ^m   Costa, Frederico ⁿ   Cwikla, Jaroslaw ^o   Herder, Wouter de ^p   Fave, Gianfranco Delle ^q   Eriksson, Barbro ^r   Falconi, Massimo ^j   Ferone, Diego ^s   Gross, David ^t   Grossman, Ashley ^u   Ito, Tetsuhide ^v   Jensen, Robert ^w   Kaltsas, Gregory ^x   Kelestimur, Fahrettin ^y   Kianmanesh, Reza ^z   Knigge, Ulrich ^aa   Kos Kudla, Beata ^ab   Krenning, Eric ^p   Mitry, Emmanuel ^ac   Nicolson, Marianne ^ad   O'Connor, Juan ^ae   O'Toole, Dermot ^af   Pape, Ulrich Frank ^ag   Pavel, Marianne ^ag   Ramage, John ^ah   Raymond, Eric ^ai   Rindi, Guido ^aj   Rockall, Andrea ^ak   Ruszniewski, Philippe ^ai   Salazar, Ramon ^al   Scarpa, Aldo ^am   Sedlackova, Eva ^an   Sundin, Anders ^g   Toumpanakis, Christos ^a   Vullierme, Marie Pierre ^ai   Weber, Wolfgang ^ao   Wiedenmann, Bertram ^ag   Zheng Pei, Zeng ^ap   more..

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^f ROYAL BROMPTON HOSPITAL   (United Kingdom)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j UNIVERSITY OF MILAN   (Italy)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l PHILIPPS UNIVERSITY MARBURG   (Germany)

^m HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁿ HOSPITAL SÍRIO LIBANÊS   (Brazil)

^o CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF INTERIOR   (Poland)

^p ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^q Universidad de Roma   (Italy)

^r UPPSALA UNIVERSITY   (Sweden)

^s UNIVERSITY OF GENOA   (Italy)

^t HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^u CHURCHILL HOSPITAL   (United Kingdom)

^v KYUSHU UNIVERSITY   (Japan)

^w NATIONAL INSTITUTES OF HEALTH   (United States)

^x UNIVERSITY OF ATHENS   (Greece)

^y School of Medicine   (Turkey)

^z UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^aa Rigshospitalet   (Denmark)

^ab MEDICAL UNIVERSITY OF SILESIA   (Poland)

^ac INSTITUT CURIE   (France)

^ad ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^ae INSTITUTO ALEXANDER FLEMING   (Argentina)

^af ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^ag CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^ah Basingstoke Hospital   (United Kingdom)

^ai BEAUJON HOSPITAL   (France)

^aj FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^ak IMPERIAL COLLEGE LONDON   (United Kingdom)

^al CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^am UNIVERSITY HOSPITAL OF VERONA   (Italy)

^an CHARLES UNIVERSITY   (Czech Republic)

^ao UNIVERSITY OF FREIBURG   (Germany)

^ap PEKING UNION MEDICAL COLLEGE   (China)

more..

Author keywords

Atypical carcinoid; Bronchial; Carcinoid; Neuroendocrine tumor; Pulmonary; Typical carcinoid

Indexed keywords

BEVACIZUMAB; CHROMOGRANIN A; CISPLATIN; CORTICOTROPIN; CYTOKERATIN; DACARBAZINE; ERLOTINIB; ETOMIDATE; EVEROLIMUS; FLUOROURACIL; GROWTH HORMONE RELEASING FACTOR; KETOCONAZOLE; KI 67 ANTIGEN; METYRAPONE; MIFEPRISTONE; OCTREOTIDE; OCTREOTIDE TETRAXETAN LU 177; OCTREOTIDE TETRAXETAN Y 90; PAZOPANIB; PENTETREOTIDE; PLACEBO; RADIOPHARMACEUTICAL AGENT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SORAFENIB; STREPTOZOCIN; TEMOZOLOMIDE; THYROID TRANSCRIPTION FACTOR 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE;

ARTICLE; BRONCHOSCOPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CARCINOID; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST RADIOGRAPHY; CUSHING SYNDROME; ECHOCARDIOGRAPHY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER METASTASIS; LIVER RESECTION; LUNG BIOPSY; LUNG FUNCTION TEST; LUNG RESECTION; METASTASIS RESECTION; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PULMONARY CARCINOID; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TUMOR DIFFERENTIATION; ANALOGS AND DERIVATIVES; CARCINOID SYNDROME; CARCINOID TUMOR; CONSENSUS DEVELOPMENT; ECHOGRAPHY; EUROPE; LUNG NEOPLASMS; MEDICAL SOCIETY; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRONCHOSCOPY; CARBOPLATIN; CARCINOID HEART DISEASE; CARCINOID TUMOR; CISPLATIN; DACARBAZINE; ETOPOSIDE; EUROPE; HUMANS; LUNG NEOPLASMS; PNEUMONECTOMY; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, SOMATOSTATIN; SOCIETIES, MEDICAL; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84941651569     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv041     Document Type: Article

References (176)

1. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39: 707-712.
2. Travis W, Brambilla E, Muller-Hermelink H et al. Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press 2004.
3. Cerilli LA, Ritter JH, Mills SE, Wick MRl. Neuroendocrine neoplasms of the lung. Am J Clin Pathol 2001; 116(Suppl): S65-S96.
4. Moran CA, Suster S, Coppola D, Wick MR. Neuroendocrine carcinomas of the lung: a critical analysis. Am J Clin Pathol 2009; 131: 206-221.
5. Wick MR. Neuroendocrine neoplasia. Current concepts. Am J Clin Pathol 2000; 113: 331-335.
6. Capella C, Heitz PU, Hofler H, Solcia E, Klöppel G. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Digestion 1994; 55(Suppl 3): 11-23.
7. Huang Q, Muzitansky A, Mark EJ. Pulmonary neuroendocrine carcinomas. A review of 234 cases and a statistical analysis of 50 cases treated at one institution using a simple clinicopathologic classification. Arch Pathol Lab Med 2002; 126: 545-553.
8. Skov BG, Krasnik M, Lantuejoul S, Skov T, Brambilla E. Reclassification of neuroendocrine tumors improves the separation of carcinoids and the prediction of survival. J Thorac Oncol 2008; 3: 1410-1415.
9. Alsina M, Marcos-Gragera R, Capdevila J et al. Neuroendocrine tumors: a population-based study of incidence and survival in Girona Province, 1994-2004. Cancer Epidemiol 2011; 35: e49-e54.
10. de Jong WK, Schaapveld M, Blaauwgeers JL, Groen HJ. Pulmonary tumors in the Netherlands: focus on temporal trends in histology and stage and on rare tumors. Thorax 2008; 63: 1096-1102.
11. Fink G, Krelbaum T, Yellin A et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 2001; 119: 1647-1651.
12. Hallgrimsson JG, Jonsson T, Johannsson JH. Bronchopulmonary carcinoids in Iceland 1955-1984. A retrospective clinical and histopathologic study. Scand J Thorac Cardiovasc Surg 1989; 23: 275-278.
13. Hauso O, Gustafsson BI, Kidd M et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008; 113: 2655-2664.
14. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001; 92: 2204-2210.
15. Levi F, Te VC, Randimbison L, Rindi G, La Vecchia C. Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97. Br J Cancer 2000; 83: 952-955.
16. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959.
17. Naalsund A, Rostad H, Strom EH, Strom EH, Lund MB, Strand TE. Carcinoid lung tumors-incidence, treatment and outcomes: a population-based study. Eur J Cardiothorac Surg 2011; 39: 565-569.
18. Perez EA, Koniaris LG, Snell SE et al. 7201 carcinoids: increasing incidence overall and disproportionate mortality in the elderly. World J Surg 2007; 31: 1022-1030.
19. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol 2001; 12: 1295-1300.
20. Skuladottir H, Hirsch FR, Hansen HH, Olsen JH. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 2002; 37: 127-135.
21. Yao JC, Hassan M, Phan A et al. One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
22. Hemminki K, Li X. Familial carcinoid tumors and subsequent cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 2001; 94: 444-448.
23. Gatta G, Ciccolallo L, Kunkler I et al. Survival from rare cancer in adults: a population-based study. Lancet Oncol 2006; 7: 132-140.
24. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995; 75: 191-202.
25. Carter D, Vazquez M, Flieder DB et al. Comparison of pathologic findings of baseline and annual repeat cancers diagnosed on CT screening. Lung Cancer 2007; 56: 193-199.
26. Pelosi G, Sonzogni A, Veronesi G et al. Pathologic and molecular features of screening low-dose computed tomography (LDCT)-detected lung cancer: a baseline and two-year repeat study. Lung Cancer 2008; 62: 202-214.
27. Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer 2008; 113: 5-21.
28. Greenberg RS, Baumgarten DA, Clark WS, Isacson P, McKeen K. Prognostic factors for gastrointestinal and bronchopulmonary carcinoid tumors. Cancer 1987; 60: 2476-2483.
29. Soga J, Yakuwa Y. Bronchopulmonary carcinoids: an analysis of 1,875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties. Ann Thorac Cardiovasc Surg 1999; 5: 211-219.
30. Faggiano A, Ferolla P, Grimaldi F et al. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian Epidemiological study: the NET MANAGEMENT study. J Endocrinol Invest 2012; 35: 817-823.
31. Hassan MM, Phan A, Li D et al. Risk factors associated with neuroendocrine tumors: a U.S.-based case-control study. Int J Cancer 2008; 123: 867-873.
32. Filosso PL, Rena O, Donati G et al. Bronchial carcinoid tumors: surgical management and long-term outcome. J Thorac Cardiovasc Surg 2002; 123: 303-309.
33. Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist 2005; 10: 123-131.
34. Broaddus RR, Herzog CE, Hicks MJ. Neuroendocrine tumors (carcinoid and neuroendocrine carcinoma) presenting at extra-appendiceal sites in childhood and adolescence. Arch Pathol Lab Med 2003; 127: 1200-1203.
35. Dishop MK, Kuruvilla S. Primary and metastatic lung tumors in the pediatric population: a review and 25-year experience at a large children's hospital. Arch Pathol Lab Med 2008; 132: 1079-1103.
36. Lal DR, Clark I, Shalkow J et al. Primary epithelial lung malignancies in the pediatric population. Pediatr Blood Cancer 2005; 45: 683-686.
37. Rizzardi G, Marulli G, Calabrese F et al. Bronchial carcinoid tumors in children: surgical treatment and outcome in a single institution. Eur J Pediatr Surg 2009; 19: 228-231.
38. Yu DC, Grabowski MJ, Kozakewich HP et al. Primary lung tumors in children and adolescents: a 90-year experience. J Pediatr Surg 2010; 45: 1090-1095.
39. Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med 2010; 134: 1628-1638.
40. Travis W, Brambilla E, Noguchi M et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
41. Beasley MB, Thunnissen FB, Brambilla E et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 2000; 31: 1255-1265.
42. Brokx HA, Risse EK, Paul MA et al. Initial bronchoscopic treatment for patients with intraluminal bronchial carcinoids. J Thorac Cardiovasc Surg 2007; 133: 973-978.
43. Erasmus JJ, McAdams HP, Patz EF, Jr et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 1998; 170: 1369-1373.
44. Froudarakis M, Fournel P, Burgard G et al. Bronchial carcinoids. A review of 22 cases. Oncology 1996; 53: 153-158.
45. Kayser K, Kayser C, Rahn W, Bovin NV, Gabius HJ. Carcinoid tumors of the lung: immuno-and ligandohistochemistry, analysis of integrated optical density, syntactic structure analysis, clinical data, and prognosis of patients treated surgically. J Surg Oncol 1996; 63: 99-106.
46. De Giorgi U, Fanini F, Amadori D et al. Tumorlets in familial history of bronchopulmonary carcinoid. J Thorac Oncol 2011; 6: 1613-1614.
47. Oliveira AM, Tazelaar HD, Wentzlaff KA et al. Familial pulmonary carcinoid tumors. Cancer 2001; 91: 2104-2109.
48. Leotlela PD, Jauch A, Holtgreve-Grez H, Thakker RV. Genetics of neuroendocrine and carcinoid tumors. Endocr Relat Cancer 2003; 10: 437-450.
49. Matsuda KM, Nobrega R, Quezado M, Schrump DS, Filie AC. Melanocytic bronchopulmonary carcinoid tumor in a patient with multiple endocrine neoplasia syndrome type 1: a case report with emphasis on intraoperative cytological findings. Diagn Cytopathol 2010; 38: 669-674.
50. Sachithanandan N, Harle RA, Burgess JR. Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1. Cancer 2005; 103: 509-515.
51. Ferolla P, Daddi N, Urbani M et al. Tumorlets, multicentric carcinoids, lymphnodal metastases, and long-term behavior in bronchial carcinoids. J Thorac Oncol 2009; 4: 383-387.
52. Rugge M, Fassan M, Clemente R et al. Bronchopulmonary carcinoid: phenotype and long-term outcome in a single-institution series of Italian patients. Clin Cancer Res 2008; 14: 149-154.
53. Travis WD, Giroux DJ, Chansky K et al. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2008; 3: 1213-1223.
54. Lou F, Sarkaria I, Pietanza C et al. Recurrence of pulmonary carcinoid tumors after resection: implications for postoperative surveillance. Ann Thorac Surg 2013; 96: 1156-1162.
55. Travis W, Colby T, Corrin B et al. Histological Typing of Lung and Pleural Tumors. Berlin, Heidelberg, New York: Springer-Verlag 1999.
56. Rindi G, Klersy C, Inzani F et al. Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer 2013; 21: 1-16.
57. Axiotis C. The neuroendocrine lung. In Li Volsi V, Asa S (eds), Endocrine Pathology. Edinburgh, New York: Churchill Livingstone 2002; 261-296.
58. Capella C, Heitz PU, Hofler H, Solcia E, Klöppel G. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Virchows Arch 1995; 425: 547-560.
59. Solcia E, Klöppel G, Sobin L. Histological Typing of Endocrine Tumors. Heidelberg: Springer 2000.
60. Li Y, Linnoila I. Multi-directional differentiation of Ascl1-defined progenitors in lung development and injury repair. Am J Respir Cell Mol Biol 2012; 47: 768-775.
61. Linnoila RI. Functional facets of the pulmonary neuroendocrine system. Lab Invest 2006; 86: 425-444.
62. Warburton D, Schwarz M, Tefft D et al. The molecular basis of lung morphogenesis. Mech Dev 2000; 92: 55-81.
63. Godwin JD, II, Brown CC. Comparative epidemiology of carcinoid and oat-cell tumors of the lung. Cancer 1977; 40: 1671-1673.
64. Bosman F, Carneiro F, Hruban R et al. WHO Classification of Tumors of the Digestive System. Lyon: International Agency for Research on Cancer (IARC) 2010.
65. Travis WD, Gal AA, Colby TV et al. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol 1998; 29: 272-279.
66. Tsuta K, Liu DC, Kalhor N, Wistuba II, Moran CA. Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas. Am J Clin Pathol 2011; 136: 252-259.
67. Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci Transl Med 2013; 5: 209ra153.
68. Zahel T, Krysa S, Herpel E et al. Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach. Virchows Arch 2012; 460: 299-308.
69. Pelosi G, Rodriguez J, Viale G, Rosai J. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol 2005; 29: 179-187.
70. Skov BG, Holm B, Erreboe A, Skov T, Mellemgaard A. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. J Thorac Oncol 2010; 5: 453-459.
71. Walts AE, Ines D, Marchevsky AM. Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors. Mod Pathol 2012; 25: 1258-1264.
72. Grimaldi F, Muser D, Beltrami CA et al. Partitioning of bronchopulmonary carcinoids in two different prognostic categories by ki-67 score. Front Endocrinol (Lausanne) 2011; 2: 20.
73. Sobin L, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumours. New York: Wiley-Blackwell 2010.
74. Rindi G, Kloppel G, Alhman H et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401.
75. Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol 2012; 36: 1761-1770.
76. Costes V, Marty-Ane C, Picot MC et al. Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and KI-67-labeling study. Hum Pathol 1995; 26: 740-745.
77. Tsuta K, Kalhor N, Raso MG, Wistuba II, Moran CA. Oncocytic neuroendocrine tumors of the lung: histopathologic spectrum and immunohistochemical analysis of 15 cases. Hum Pathol 2011; 42: 578-585.
78. Warth A, Fink L, Fisseler-Eckhoff A et al. Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids. Virchows Arch 2013; 462: 507-513.
79. Phan AT, Oberg K, Choi J et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas 2010; 39: 784-798.
80. Miller RR, Muller NL. Neuroendocrine cell hyperplasia and obliterative bronchiolitis in patients with peripheral carcinoid tumors. Am J Surg Pathol 1995; 19: 653-658.
81. Gosney JR, Williams IJ, Dodson AR, Foster CR. Morphology and antigen expression profile of pulmonary neuroendocrine cells in reactive proliferations and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH). Histopathology 2011; 59: 751-762.
82. Rossi G, Cavazza A, Graziano P, Papotti M. mTOR/p70S6K in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Am J Respir Crit Care Med 2012; 185: 341. author reply-2.
83. Nassar AA, Jaroszewski DE, Helmers RA et al. Diffuse idiopathic pulmonary neurendocrine cell hyperplasia: a systematic overview. Am J Respir Crit Care Med 2011; 184: 8-16.
84. Walker CM, Vummidi D, Benditt JO, Godwin JD, Pipavath S. What is DIPNECH? Clin Imaging 2012; 36: 647-649.
85. Koo CW, Baliff JP, Torigian DA et al. Spectrum of pulmonary neuroendocrine cell proliferation: diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, tumorlet, and carcinoids. AJR Am J Roentgenol 2010; 195: 661-668.
86. Schmitt AM, Riniker F, Anlauf M et al. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol 2008; 32: 420-425.
87. Hermann G, Konukiewitz B, Schmitt A, Perren A, Klöppel G. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2. Virchows Arch 2011; 459: 147-154.
88. Miremadi A, Pinder SE, Lee AH et al. Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology 2002; 40: 215-222.
89. Sapino A, Papotti M, Righi L et al. Clinical significance of neuroendocrine carcinoma of the breast. Ann Oncol 2001; 12(Suppl 2): S115-S117.
90. Righi L, Volante M, Tavaglione V et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumors: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann Oncol 2010; 21: 548-555.
91. Ferolla P, Faggiano A, Mansueto G et al. Biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. J Endocrinol Invest 2008; 31: 277-286.
92. Bajetta E, Ferrari L, Martinetti A et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999; 86: 858-865.
93. Baudin E, Gigliotti A, Ducreux M et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 1998; 78: 1102-1107.
94. Lim E, Goldstraw P, Nicholson AG et al. Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007. J Thorac Oncol 2008; 3: 1194-1201.
95. Öberg K, Hellman P, Ferolla P, Papotti M, ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(S7): vii120-3.
96. Daddi N, Ferolla P, Urbani M et al. Surgical treatment of neuroendocrine tumors of the lung. Eur J Cardiothorac Surg 2004; 26(4): 813-817.
97. Kaltsas G, Androulakis II, de Herder WW, Grossman AB. Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer 2010; 17: R173-R193.
98. Thakker RV, Newey PJ, Walls GV et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012; 97: 2990-3011.
99. Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658-5671.
100. Jeung MY, Gasser B, Gangi A et al. Bronchial carcinoid tumors of the thorax: spectrum of radiologic findings. Radiographics 2002; 22: 351-365.
101. Meisinger QC, Klein JS, Butnor KJ, Gentchos G, Leavitt BJ. CT features of peripheral pulmonary carcinoid tumors. AJR Am J Roentgenol 2011; 197: 1073-1080.
102. Schrevens L, Vansteenkiste J, Deneffe G et al. Clinical-radiological presentation and outcome of surgically treated pulmonary carcinoid tumors: a long-term single institution experience. Lung Cancer 2004; 43: 39-45.
103. García-Yuste M, Matilla JM, Cueto A et al.; Members of the Spanish Multicenter Study of Neuroendocrine Tumors of the Lung by the Spanish Society of Pneumonology and Thoracic Surgery (EMETNE-SEPAR). Typical and atypical carcinoid: analysis of the experience of the Spanish multicenter study of neuroendocrine tumors of the lung. Eur J Cardio Thorac Surg 2007; 31: 192-197.
104. Bhosale P, Shah A, Wei W et al. Carcinoid tumours: predicting the location of the primary neoplasm based on the sites of metastases. Eur Radiol 2013; 23: 400-407.
105. Sundin A, Vullierme MP, Kaltsas G, Plöckinger U. Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological examinations. Neuroendocrinology 2009; 90: 167-183.
106. Leboulleux S, Dromain C, Vataire AL et al. Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 2008; 93: 3021.
107. Ambrosini V, Nanni C, Zompatori M et al. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2010; 37: 722-727.
108. Granberg D, Sundin A, Janson ET et al. Octreoscan in patients with bronchial carcinoid tumors. Clin Endocrinol (Oxf ) 2003; 59: 793-799.
109. Abgral R, Leboulleux S, Déandreis D et al. Performance of (18) fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab 2011; 96: 665-671.
110. Park CM, Goo JM, Lee HJ et al. Tumors in the tracheobronchial tree: CT and FDG PET features. Radiographics 2009; 29: 55-71.
111. Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett JR. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest 2007; 131: 255-260.
112. Pattenden H, Beddow E, Dusmet M et al. Test performance of PET-CT for mediastinal lymph node staging of pulmonary carcinoid tumors. J Clin Oncol 2013; 31: (suppl; abstr 7544).
113. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun 2009; 30: 281-286.
114. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-518.
115. 18FFDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009; 50: 1927-1932.
116. 111In-DTPA-octreotide scintigraphy. J Nucl Med 2010; 51: 875-882.
117. 64Cu-DOTATATE: first-in-humans study. J Nucl Med 2012; 53: 1207-1215.
118. Orlefors H, Sundin A, Garske U et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005; 90: 3392-3400.
119. Rivera MP, Detterbeck F, Mehta AC; American College of Chest Physicians. Diagnosis of lung cancer: the guidelines. Chest 2003; 123(1 Suppl): 129S-136S.
120. Steinfort DP, Finlay M, Irving LB. Diagnosis of peripheral pulmonary carcinoid tumor using endobronchial ultrasound. Ann Thorac Med 2008; 3: 146-148.
121. Sarraf KM, Belcher E, Price S, Lim E. Clinical application of direct bronchial ultrasound to visualize and determine endobronchial tumor margins for surgical resection. Ann Thorac Surg 2008; 86: 1339-1341.
122. Banki F. Pulmonary assessment for general thoracic surgery. Surg Clin North Am 2010; 90: 969-984.
123. Plockinger U, Gustafsson B, Ivan D, Szpak W, Davar J. Consensus guidelines for the standards of care in neuroendocrine tumors: echocardiography. Neuroendocrinology 2009; 90: 190-193.
124. Cheitlin MD, Armstrong WF, Aurigemma GP et al. ACC/AHA/ASE 2003 guidelines uptake for the clinical application of echocardiograph: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr 2003; 16: 1091-1110.
125. Goldstraw P. International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology. Florida, USA: Editorial Rx Press 2009.
126. Detterbeck FC. Management of carcinoid tumors. Ann Thorac Surg 2010; 89: 998-1005.
127. Lim E, Yap YK, De Stavola BL, Nicholson AG, Goldstraw P. The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors. J Thorac Cardiovasc Surg 2005; 130: 969-972.
128. Glazer ES, Tseng JF, Al-Refaie W et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford) 2010; 12: 427-433.
129. Pavel M, Baudin E, Couvelard A et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95: 157-176.
130. Okike N, Bernatz PE, Woolner LB. Carcinoid tumors of the lung. Ann Thorac Surg 1976; 22: 270-277.
131. Vadasz P, Palffy G, Egervary M, Schaff Z. Diagnosis and treatment of bronchial carcinoid tumors: clinical and pathological review of 120 operated patients. Eur J Cardiothorac Surg 1993; 7: 8-11.
132. Hurt R, Bates M. Carcinoid tumours of the bronchus: a 33 year experience. Thorax 1984; 39: 617-623.
133. Francioni F, Rendina EA, Venuta F et al. Low grade neuroendocrine tumors of the lung (bronchial carcinoids)-25 years' experience. Eur J Cardiothorac Surg 1990; 4: 472-476.
134. Stamatis G, Freitag L, Greschuchna D. Limited and radical resection for tracheal and bronchopulmonary carcinoid tumour. Report on 227 cases. Eur J Cardiothorac Surg 1990; 4: 527-532. discussion 533.
135. Beshay M, Roth T, Stein R, Schmid RA. Synchronous bilateral typical pulmonary carcinoid tumors. Eur J Cardiothorac Surg 2003; 23: 251-253.
136. Spaggiari L, Veronesi G, Gasparri R, Pelosi G. Synchronous bilateral lung carcinoid tumors: a rare entity? Eur J Cardiothorac Surg 2003; 24: 334-337.
137. Rea F, Rizzardi G, Marulli G, Bortolotti L. Metachronous bronchial carcinoid tumor. Eur J Cardiothorac Surg 2006; 30: 394-396.
138. Bertoletti L, Elleuch R, Kaczmarek D, Jean-François R, Vergnon JM. Bronchoscopic cryotherapy treatment of isolated endoluminal typical carcinoid tumor. Chest 2006; 130: 1405-1411.
139. Cavaliere S, Foccoli P, Farina PL. Nd:YAG laser bronchoscopy. A five-year experience with 1,396 applications in 1,000 patients. Chest 1988; 94: 15-21.
140. Cao C, Yan TD, Kennedy C et al. Bronchopulmonary carcinoid tumors: long-term outcomes after resection. Ann Thorac Surg 2011; 91: 339-343.
141. Bertino EM, Confer PD, Colonna JE, Ross P, Otterson GA. Pulmonary euroendocrine/carcinoid tumors: a review article. Cancer 2009; 115: 4434-4441.
142. Oberg K, Ferone D, Kaltsas G et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy. Neuroendocrinology 2009; 90: 209-213.
143. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010; 31: 169-188.
144. Filosso PL, Ruffini E, Oliaro A et al. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg 2002; 21: 913-917.
145. Aparicio T, Ducreux M, Baudin E et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001; 37: 1014-1019.
146. Ducreux M, Ruszniewski P, Chayvialle JA et al. The antitumoral effect of the longacting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000; 95: 3276-3281.
147. Faiss S, Pape UF, Böhmig M et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21: 2689-2696.
148. Rinke A, Müller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663.
149. Caplin M, Ruszniewski P, Pavel M et al. A randomized, double-blind, placebocontrolled study of lanreotide antiproliferative response in patients with gastroenteropancreatic neuroendocrine tumors (CLARINET). In Paper Presented at The European Cancer Congress, Amsterdam, Netherlands, 27 September-1 October 2013.
150. Steinmüller T, Kianmanesh R, Falconi M et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008; 87: 47-62.
151. Kos-Kudla B, O'Toole D, Falconi M et al. ENETS consensus guidelines for the management of bone and bronchial metastases from neuroendocrine tumors. Neuroendocrinology 2010; 91: 341-350.
152. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12: 941-945.
153. 90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011; 29: 2416-2423.
154. 3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130.
155. 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging 2007; 34: 1219-1227.
156. Sun W, Lipsitz S, Catalano P et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005; 23: 4897-4904.
157. Brizzi MP, Berruti A, Ferrero A et al. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer 2009; 9: 388.
158. Bajetta E, Catena L, Procopio G et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumors? Cancer Chemother Pharmacol 2007; 59: 637-642.
159. Pavel M, Grossman A, Arnold R et al. ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors. Neuroendocrinology 2010; 91: 326-332.
160. Kulke MH, Scherubl H. Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res 2009; 3(5 Suppl 2):S62-S66.
161. Granberg D, Eriksson B, Wilander E et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 2001; 12(10): 1383-1391.
162. Turner NC, Strauss SJ, Sarker D et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010; 102: 1106-1112.
163. Meyer T, Qian W, Caplin ME et al. Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. Eur J Cancer 2014; 50: 902-911.
164. Wirth LJ, Carter MR, Jänne PA, Johnson BE. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer 2004; 44: 213-220.
165. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005; 8: 179-183.
166. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364(6): 514-523.
167. Pavel ME, Hainsworth JD, Baudin E et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378: 2005-2012.
168. Pavel ME, Wiedenmann B, Capdevila J et al. RAMSETE: a single-arm, multicenter, single-stage phase II trial of RAD001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in Europe. J Clin Oncol 2012; 30: (suppl; abstr 4122).
169. Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513.
170. Kulke MH, Lenz HJ, Meropol NJ et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403-3410.
171. Grande E, Castellano D, García-Carbonero R et al. PAZONET: a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients ( pts), on behalf of the Spanish Task Force for NETs (GETNE). In Paper Presented at ESMO, Vienna, 2012. Abstract 11570.
172. Yao JC, Phan A, Hoff PM et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26: 1316-1323.
173. Castellano D, Capdevila J, Sastre J et al. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). Eur J Cancer 2013; 49: 3780-3787.
174. Chan JA, Stuart K, Earle CC et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 2012; 30: 2963-2968.
175. Karpathakis A, Caplin M, Thirlwell C. Hitting the target: where do molecularly targeted therapies fit in the treatment scheduling of neuroendocrine tumours? Endocr Relat Cancer 2012; 19: R73-R92.
176. Warren WH, Gould VE. Long-term follow-up of classical bronchial carcinoid tumors. Clinicopathologic observations. Scand J Thorac Cardiovasc Surg 1990; 24: 125-130.